explore -WSS

explore

author：hotspot 2025-09-29 13:09:59 - browse：28

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Will generative AI in health care meet the fate of IBM's Dr. Watson?

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Merck drug for rare lung condition set for approval in U.S.

Letters to First Opinion on caregivers, digital health, and more

See how much Covid

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ultragenyx gene therapy for rare liver ailment succeeds in late

Peter Hotez and the public health issue of online harassment

At ASCO, AstraZeneca reports strong data for breast cancer drug

Apple is now the first public company to be valued at $3 trillion

Ionis drug prevents swelling attacks due to hereditary angioedema

Trump demands the U.S. pay no more for drugs than other countries … again

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Hollywood unions extend contract negotiations for actors

Merck drug for rare lung condition set for approval in U.S.

entertainment

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Why the world’s most expensive drug might be worth the price

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Primary care physicians play key roles in Alzheimer's management

Readout Newsletter: Merck, Vertex, and Viking updates

knowledge

Wikipedia

Wikipedia

explore